Citations

Clear

3042 citation(s) found for "Kumar, S".

Updates on Anti-Obesity Medications in Children and Adolescents
Hassan, Doha , Kumar, Seema , Kumar, Seema , Salama, Mostafa

Mayo Clinic

Children | October 15, 2025 | Volume: 12 | Issue: 10 | Pages: 1390

10.3390/children12101390 | PMID 41153573 Get It

Childhood obesity has assumed epidemic proportions; it results from a complex interplay of genetic, physiological, socioeconomic, and environmental factors. It is associated with numerous short- and long-term health complications, including cardiometabolic and psychosocial consequences. While lifestyle modifications remain the cornerstone of treatment, their overall impact is modest. As a result, pharmacotherapy is increasingly recommended as an adjunct in selected pediatric patients, particularly those with severe or refractory obesity. In recent years, several anti-obesity medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, have shown promise in pediatric populations, particularly adolescents. However, the pharmacologic options remain limited for younger children. This review summarizes current evidence on the efficacy and safety of available anti-obesity medications in children and adolescents, offering practical, age-based strategies to guide the appropriate clinical use of these medications as part of a comprehensive obesity-management plan.
Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma
Madamsetty, Vijay Sagar , Rachamala, Hari Krishnareddy, Dutta, Shamit K., Wang, Enfeng , Pal, Krishnendu , Mukhopadhyay, Debabrata , Dutta, Shamit Kumar, Mukhopadhyay, Debabrata , Pal, Krishnendu , Madamsetty, Vijay S

Mayo Clinic

Pharmaceutics | October 15, 2025 | Volume: 17 | Issue: 10 | Pages: 1334

10.3390/pharmaceutics17101334 | PMID 41155969 Get It

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive tumor biology, poor vascularization, dense stromal barriers, and profound resistance to chemotherapy. GAIP-interacting protein C-terminus 1 (GIPC1), a PDZ-domain-containing adaptor protein, is highly overexpressed in PDAC and plays a critical role in tumor progression and chemoresistance. This study aimed to develop and evaluate a novel tumor-targeted liposomal siRNA delivery system (LGIPCsi) to silence GIPC1 and enhance the therapeutic efficacy of gemcitabine (GEM) in PDAC; Methods: LGIPCsi nanoparticles were synthesized and optimized for physicochemical stability, siRNA complexation efficiency, and tumor-targeting capability. Their therapeutic efficacy was assessed using in vitro pancreatic cancer cell models and in vivo orthotopic and patient-derived xenograft (PDX) models of PDAC. Biodistribution, tumor uptake, and antitumor efficacy were evaluated following systemic administration. Combination studies were performed to assess the synergistic effects of LGIPCsi and GEM; Results: GIPC1 silencing significantly sensitized pancreatic cancer cells to GEM, resulting in enhanced inhibition of tumor cell proliferation in vitro. In vivo, systemic administration of LGIPCsi achieved efficient intratumoral delivery of siGIPC1, leading to marked tumor growth suppression. Combination therapy with GEM and LGIPCsi produced synergistic antitumor effects, with substantial tumor regression compared to monotherapy groups. Importantly, no significant systemic toxicity was observed in treated animals; Conclusions: This study identifies GIPC1 as a promising therapeutic target in PDAC and demonstrates that tumor-targeted siRNA nanomedicine can effectively overcome chemoresistance when combined with standard chemotherapy. The LGIPCsi platform offers a rational and translational strategy to enhance treatment efficacy in PDAC through targeted RNAi-based combination therapy.
Change of guard at Amyloid – a tribute to outgoing Editor in Chief, Professor Per Westermark
Kumar, Shaji

Mayo Clinic

Amyloid | October 15, 2025 | Volume: 32 | Issue: 4 | Pages: 301-302

10.1080/13506129.2025.2574101 | PMID 41089037 Get It

Neuroimaging Patterns of Breakthrough Stroke in Patients on Therapeutic Anticoagulation
Itrat, Ahmed , Gallegos, Patrick, Kumar, Ashish, Mullen, Chanda, Mahalwar, Gauranga, Itrat, Ahmed , Gallegos, Patrick, Kumar, Ashish, Mullen, Chanda, Mahalwar, Gauranga

Mayo Clinic

Clinical Neuroimaging | October 10, 2025 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/neo2.70040 Get It

ABSTRACT Background and Purpose Neuroimaging of acute ischemic stroke (AIS) may provide clues to the underlying mechanism based on stroke location. Patients who experience stroke despite therapeutic anticoagulation provide a clinical challenge, and the subsequent preventive regimen may depend on the underlying stroke mechanism. We conducted a retrospective analysis of patients presenting with stroke despite anticoagulation (AC+) and compared their imaging findings to those of patients with stroke while not on anticoagulation (AC−). Methods Retrospectively, patients hospitalized with AIS were categorized as AC+ and AC− based on their prehospital anticoagulation use. A total of 119 patients met the inclusion criteria for AC+ strokes, which were compared to a random sample of 135 AC− patients during the same time frame. Imaging was dichotomized into embolic (ES) and nonembolic stroke (NES) groups. Descriptive analyses were used to compare imaging appearance between the two groups. Secondary analyses using multivariate logistic regression were used to identify risk factors for strokes in the AC+ group. Results ES were proportionally higher among the AC+ group compared to the AC− cohort. Atrial fibrillation was an independent predictor for breakthrough stroke among the entire cohort (adjusted OR 69.8 [21.1–291.8], p < 0.001), as well as a predictor for ES among those with AC+ stroke (adjusted OR 55.29 [14.4–286.2], p < 0.001). Conclusions AC+ patients have a higher proportion of embolic appearing strokes, suggesting incomplete response to anticoagulation rather than competing mechanisms as the cause of stroke in these patients. Further investigation into stroke mechanisms and management in this unique population is needed.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions
Maura, Francesco , Bergsagel, P. Leif , Kumar, Shaji , Maclachlan, Kylee , Derkach, Andriy , Garcés, Juan‐José , Firestone, Ross , Braggio, Esteban , Asmann, Yan W. , Papadimitriou, Marios , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Lionetti, Marta , Matera, Antonio , Pioggia, Stefania, Vià, Matteo Da , Magistris, Claudio De, Siegel, Erin M. , Agius, Phaedra , Teer, Jamie K. , Yamashita, Yusuke , Silva, Ariosto S. , Blaney, Patrick , Patel, Krina K. , Campbell, Peter J. , Morgan, Gareth , Orlowski, Robert Z. , Shain, Kenneth H. , Bolli, Niccolò , Bergsagel, P. Leif , Kumar, Shaji K , Maclachlan, Kylee , Derkach, Andriy , Garces, Juan-Jose , Firestone, Ross , Braggio, Esteban , Asmann, Yan, Durante, Michael , Diamond, Benjamin T , Hultcrantz, Malin , Marella, Alessio , Castellano, Giancarlo , Maeda, Akihiro , Lionetti, Marta , Matera, Antonio , Da Vià, Matteo C , de Magistris, Claudio , DeAvila, Danny , Sudalagunta, Praneeth Reddy , Canevarolo, Rafael Renatino , Siegel, Erin M , Teer, Jamie K , McPherson, Andrew , Yamashita, Yusuke , Blaney, Patrick , Baz, Rachid , Patel, Krina , Fonseca, Rafael , Landgren, C Ola , Orlowski, Robert Z. , Shain, Kenneth H , Bolli, Niccolo' , Usmani, Saad , Rajkumar, S Vincent , Maura, Francesco , Ziccheddu, Bachisio , Durante, Michael , Diamond, Benjamin , Leongamornlert, Daniel , Fonseca, Rafaël , Landgren, Ola , Usmani, Saad Z. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | October 8, 2025 | Volume: 44 | Issue: 3 | Pages: 188-199

10.1200/jco-25-01733 | PMID 41061199 Get It

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
Charalampous, Charalampos , Parrondo, Ricardo , Nagaraj, Madhu , Rodríguez‐Otero, Paula , Iida, Shinsuke , Raab, Marc S. , Mateos, María‐Victoria , Duh, Mei Sheng , Bobbili, Priyanka , Chen, Jingyi , Chaudhary, Mohammad A. , Hlavacek, Patrick , Nador, Guido, DiBonaventura, Marco , Goldman, Erinn Hoag, Hughes, David , Kumar, Shaji , Raab, Marc S , Parrondo, Ricardo D , Rodriguez-Otero, Paula , Chhabra, Saurabh , Nagaraj, Madhu , Wang, Aolin , Mohty, Mohamad

Mayo Clinic

JCO Oncology Advances | October 7, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00009 Get It

PURPOSE This analysis aimed to contextualize the symptoms of peripheral neuropathy (PN) experienced by patients with triple-class refractory (TCR) multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 clinical trial with those experienced by patients with TCR MM receiving a new line of physician's choice of therapy in the real-world MagnetisMM-14 study. METHODS MagnetisMM-3 included 123 patients and MagnetisMM-14 included 35 who had TCR MM and were enrolled under the same eligibility criteria. Patient-reported symptoms of PN were collected monthly using the Chemotherapy-Induced Peripheral Neuropathy-20 item (CIPN20) questionnaire and compared for clinically meaningful differences across sensory, motor, and autonomic domains. Higher scores indicated worse patient-reported PN symptoms. RESULTS Baseline demographics and clinical characteristics for patients in MagnetisMM-3 and MagnetisMM-14 were generally similar. Patients in MagnetisMM-3 had a median of five ( v four in MagnetisMM-14) prior lines of therapy. In MagnetisMM-14, common index therapies included elotuzumab + pomalidomide (23%), carfilzomib + pomalidomide (19%), or carfilzomib + cyclophosphamide (19%), all with corticosteroids. Mean scores for sensory (15.8 v 14.8) and motor (14.4 v 12.2) domains of the CIPN20 were similar between MagnetisMM-3 and MagnetisMM-14 at baseline. Mean scores for the autonomic domain were 14.0 versus 21.3 at baseline, respectively. No clinically meaningful differences for any domain were found between month 6 scores or changes in scores from baseline to month 6 between MagnetisMM-3 and MagnetisMM-14 populations. CONCLUSION These findings suggest that elranatamab treatment was not associated with a worsening of patient-reported PN symptoms across the sensory, motor, and autonomic domains of the CIPN20. Moreover, PN symptoms reported with elranatamab treatment were similar to those reported with other common therapies used in real-world clinical practice for the management of MM. MagnetisMM-3 ClinicalTrials.gov identifier: NCT04649359 .
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
Bolarinwa, Abiola , Zanwar, Saurabh , Abdallah, Nadine , Hayman, Suzanne R. , Gertz, Morie A. , Muchtar, Eli , Kapoor, Prashant , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Dingli, David , Warsame, Rahma , Binder, Moritz , Lin, Yi , Hwa, Yi L. , Rogers, Michelle, Hobbs, Miriam, Fonder, Amie , Kumar, Shaji , Gertz, Morie A , Dispenzieri, Angela , Muchtar, E , Gonsalves, Wilson , Kourelis, Taxiarchis , Dingli, David , Warsame, Rahma , Leung, Nelson , Cook, Joselle M , Binder, Moritz , Hwa, Yi L , Rogers, Michelle G, Jevremovic, Dragan , Rajkumar, S Vincent , Kumar, Shaji K , Bolarinwa, Abiola B , Buadi, Francis K. , Dispenzieri, Angela , Leung, Nelson , Cook, Joselle , Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | October 4, 2025 | Volume: 100 | Issue: 12 | Pages: 2286-2292

10.1002/ajh.70099 | PMID 41045034 Get It

ABSTRACT Light chain multiple myeloma (LCMM) is a subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains and accounts for 15%–20% of newly diagnosed MM. A comprehensive comparison of LCMM with MM producing intact immunoglobulin (non‐LCMM) remains limited. In this retrospective study, we described distinct clinical and cytogenetic features and assessed long‐term outcomes in 852 LCMM patients diagnosed between 01/01/2004 and 12/31/2022, compared with non‐LCMM controls matched for age, sex, and year of diagnosis. On univariable analysis, LCMM patients were more likely to present with elevated creatinine (> 2 mg/dL), beta‐2‐microglobulin ≥ 5.5 mg/L, elevated LDH, hypercalcemia, t(11;14), del(13q), and t(6;14). Conversely, IMS‐IMWG high‐risk disease, hyperdiploidy, t(4;14), and serum albumin < 3.5 g/dL were less common. On multivariable analysis, elevated creatinine (OR: 5.1, 95% CI: 1.2–27, p = 0.04), t(11;14) (OR: 2.6, 95% CI: 1.3–5.2, p = 0.006), and del(13q) (OR: 4.1, 95% CI: 2.1–8.2, p < 0.001) were independently associated with LCMM, while IMS‐IMWG high‐risk disease (OR: 0.3, 95% CI: 0.1–0.8, p = 0.02) and hyperdiploidy (OR: 0.3, 95% CI: 0.1–0.7, p = 0.002) were less frequent. Despite these differences, progression‐free survival with frontline treatment (HR: 0.97, 95% CI: 0.84–1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87–1.13, p = 0.94) were similar between LCMM and non‐LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS‐IMWG high‐risk disease, and comparable survival outcomes.
Cephalic Vein Interposition Graft for Salvage of Compromised DIEP Flap in Breast Reconstruction
Kumar, Nishant , Odorico, Scott K. , Vijayasekaran, Aparna , Odorico, Scott K , Vijayasekaran, Aparna , Bustos, Samyd S.

Mayo Clinic

Microsurgery | October 3, 2025 | Volume: 45 | Issue: 7 | Pages: No page available

10.1002/micr.70124 | PMID 41042018 Get It

ABSTRACT The deep inferior epigastric perforator (DIEP) flap remains the preferred flap option for autologous breast reconstruction following mastectomy. This case report presents the novel use of the cephalic vein (CV) as an interposition graft to alleviate venous congestion in a patient undergoing DIEP flap reconstruction. A 42‐year‐old woman experienced venous congestion following her initial autologous reconstruction, attributed to thrombus formation from kinking of the vascular pedicle. Despite initial attempts to resolve the congestion, the condition persisted. Since the flap was based on a single perforator, we decided to attempt a CV turndown. The CV was noted to be attenuated and not feasible for use in turndown; therefore, venous salvage was completed by using the CV as an interposition graft to bypass the affected flap vena comitans. The procedure successfully restored venous flow, allowing for flap salvage and subsequent healing. This case underscores the potential of CV as an interposition graft in autologous breast reconstruction, particularly when traditional CV turndown is not possible due to vessel attenuation.
Monoclonal Gammopathy of Undetermined Significance
Kumar, Shaji, Rajkumar, S. Vincent , Kumar, Shaji

Mayo Clinic

New England Journal of Medicine | October 1, 2025 | Volume: 393 | Issue: 13 | Pages: 1315-1326

10.1056/nejmra2412716 | PMID 41032708 Get It

Assessing Alignment of Referrals with Guidelines for the Treatment of Children with Obesity
Borkar, Shalmali R. , Kumar, Seema, Biggs, Bridget K , Standen, Erin C, Biggs, Bridget K. , Standen, Erin C. , Menser, Terri

Mayo Clinic

Childhood Obesity | September 30, 2025 | Volume: 21 | Issue: 8 | Pages: 682-687

10.1177/21532176251370126 | PMID 40833824 Get It

It is unknown how many children with obesity are offered treatments aligned with clinical practice guidelines. This study examined electronic medical record data from a Midwest, USA, health system to quantify referrals to obesity treatment among patients 2–17 years old with obesity presenting for well-child visits in 2022 and/or 2023. Mixed-effects logistic regression models tested associations of referral placement with child characteristics, the Area Deprivation Index, and distance to specialty care. Of 14,893 patients, 591 (4.0%) received a referral. Referrals were associated with severe obesity ( p < 0.001), older age ( p < 0.001), proximity to specialty care ( p < 0.001), number of well-visits ( p ≤ 0.001), and identification with a minoritized race or ethnicity ( p < 0.05–0.001). Findings indicate a large gap from the current state of referrals to alignment with practice guidelines for pediatric obesity. Furthermore, research needs to explore and address barriers to referrals and treatment access.